# A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

> **NCT06990880** · PHASE1,PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 85 (estimated)

## Conditions studied

- Neoplasms, Prostate

## Interventions

- **DRUG:** GSK5458514

## Key facts

- **NCT ID:** NCT06990880
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2027-10-26
- **Final completion:** 2028-08-09
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990880, "A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06990880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*